https://www.selleckchem.com/pr....oducts/fluzoparib.ht
Clarification of the detailed mechanisms involved is anticipated. Lung cancer is still the first cause of cancer-related deaths worldwide. The development of immune checkpoint inhibitors (ICI) has drastically changed the prognosis of some patients, but the rate of long responders does not exceed 20%. Moreover, ICIs are not adverse events-free and remain expensive. Therefore, predictive biomarkers of long-term benefit to ICI are required. The two main fields being evaluated currently are PD-L1 expression and tumor mutational burden (T
Like
Comment
Share
